Akebia Therapeutics, Inc.
AKBA Healthcare Drug Manufacturers Specialty & Generic
Akebia Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $236.2 million, up 47.5% from fiscal 2024. In the quarter to June 2026, revenue fell 21.4%, EPS fell 3,433.3%, free cash flow fell 89.0% and total debt rose 5.31%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow AKBA
Akebia Therapeutics, Inc. (AKBA) Piotroski F-score
Akebia Therapeutics, Inc.'s Piotroski F-score for fiscal 2025 is 7 out of 9: 7 of nine tests of profitability, leverage and efficiency passed, up from 3 in fiscal 2024.
Piotroski F-score, annual
Embed this chart
Annual newest first
| Period | Piotroski F-score | Change (points) |
|---|---|---|
| FY2025 | 7 | 4.00 |
| FY2024 | 3 | 0.00 |
| FY2023 | 3 | (3.00) |
| FY2022 | 6 | 4.00 |
| FY2021 | 2 | (1.00) |
| FY2020 | 3 | 1.00 |
| FY2019 | 2 | (1.00) |
| FY2018 | 3 | — |
How fiscal 2025’s score is made up
| Test | This year | Year before | Result | Points |
|---|---|---|---|---|
| Positive return on assets | (1.79%) | (30.02%) | Fail | 0 |
| Positive operating cash flow | 67.99m | (40.66m) | Pass | 1 |
| Rising return on assets | (1.79%) | (30.02%) | Pass | 1 |
| Cash flow above net income | 73.34m | 28.75m | Pass | 1 |
| Falling long-term leverage | 0.16 | 0.17 | Pass | 1 |
| Rising current ratio | 1.55 | 1.41 | Pass | 1 |
| No new shares issued | 257,158,000 | 210,947,000 | Fail | 0 |
| Rising gross margin | 83.29% | 60.56% | Pass | 1 |
| Rising asset turnover | 0.79 | 0.69 | Pass | 1 |
| Piotroski F-score | Strong — most fundamentals improved | 7 | ||
How the Piotroski F-score works
One point for each of nine tests, this fiscal year against the one before: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, a rising current ratio, no new shares issued, a rising gross margin and rising asset turnover. The ratios are the ones on this site, so each can be checked.
Joseph Piotroski (2000) called 8–9 high and 0–1 low; reading it in three bands is the common convention:
| 7–9 | Strong — most fundamentals improved |
|---|---|
| 4–6 | Mixed |
| 0–3 | Weak — most fundamentals deteriorated |
Where this differs from the paper: return on assets is on average rather than beginning-of-year assets, and weighted basic shares stand in for shares issued. The score is shown only when all nine tests can be worked out, which takes three fiscal years; banks and insurers, which report no current assets or gross profit, have none.
Piotroski F-score against peers
| Company | Piotroski F-score |
|---|---|
| AKBA Akebia Therapeutics, Inc. | 7 |
| ANIK Anika Therapeutics Inc. compare | 6 |
| SIGA Siga Technologies Inc. compare | 5 |
| ORGO Organogenesis compare | 4 |
| DERM Journey Medical Corporation compare | 4 |
| ACB Aurora Cannabis Inc. compare | 4 |
| LFCR Lifecore Biomedical, Inc. compare | 3 |
| BIOA BioAge Labs, Inc. compare | — |
| CRDL Cardiol Therapeutics Inc. compare | — |
What Piotroski F-score is
The Piotroski F-Score tells an investor how many signs of improving profitability, funding and efficiency a company shows against a year earlier.
One point for each of nine tests against a year earlier: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, rising current ratio, no new shares issued, rising gross margin, and rising asset turnover